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An overview on the treatment of 
postmenopausal osteoporosis
Uma visão geral sobre o tratamento da osteoporose pós-menopausa
Sergio Setsuo Maeda1, Marise Lazaretti-Castro2
ABSTRACT
Osteoporosis is a worldwide health problem related to the aging of the population, and it is often un-
derdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the 
quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The 
lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporo-
sis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, 
and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active 
medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, 
bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). 
Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti-
-resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse 
effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel 
drugs were developed and are being assessed in clinical trials. Arq Bras Endocrinol Metab. 2014;58(2):162-71
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RESUMO
A osteoporose é um problema de saúde mundial relacionada com o envelhecimento da população e 
muitas vezes é subdiagnosticada e subtratada. Relaciona-se à significativa morbidade, mortalidade 
e redução da qualidade de vida. A deficiência de estrogênio é o principal fator que contribui para a 
perda óssea após a menopausa. O risco de fratura a partir dos 50 anos de idade é de cerca de 50% em 
mulheres. O objetivo do tratamento da osteoporose é a prevenção de fraturas. O tratamento não far-
macológico envolve uma dieta saudável, prevenção de quedas e de programas de exercícios físicos. 
O tratamento farmacológico inclui cálcio, vitamina D e medicação ativa em tecido ósseo, tais como 
antirreabsortivos (SERMs, terapia de substituição hormonal, bifosfonatos, denosumabe), formado-
res de osso (PTH e análogos) e agentes mistos (ranelato de estrôncio). Os bisfosfonatos (alendrona-
to, risedronato, ibandronato e zoledronato) são os mais utilizados agentes antirreabsortivos para o 
tratamento da osteoporose. A baixa aderência, a intolerância medicamentosa e os efeitos adversos 
podem limitar os benefícios do tratamento. Com base no conhecimento da sinalização entre as célu-
las ósseas, novos medicamentos foram desenvolvidos e estão sendo avaliados em ensaios clínicos. 
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INTRODUCTION
P ostmenopausal osteoporosis is a silent disease in most cases, with no symptoms until fractures oc-
cur. It is characterized by low bone mineral density 
(BMD) and changes in bone microarchitecture that re-
duce bone strength and increase fracture risk (1).
Estrogen deficiency is the major contributing factor 
to bone loss after menopause. Estrogens decrease dur-
ing the climacteric period induce an increase in RANK-
ligand (RANKL) and a decrease in osteoprotegerin 
(OPG) secretion from osteoblasts. RANKL activates its 
RANK receptor on the surface of the pre-osteoclasts, 
which induces their differentiation and activation. This 
imbalance induces fast bone loss, and increases the risk 
of fractures. 
This condition is frequently underdiagnosed and 
undertreated. The World Health Organization (WHO) 
has identified osteoporosis as a major public health con-
cern, due to its high prevalence and the serious conse-
quences of osteoporotic fractures (2).
http://dx.doi.org/10.1590/0004-2730000003039
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In the present, the lifetime fracture risk at 50 years 
of age is about 50% in women. Osteoporosis causes 
lasting disability, increased mortality, and poor qual-
ity of life. The cost of managing osteoporotic fractures 
imposes a huge burden on healthcare systems, and will 
increase over the next years because of the aging of the 
population (1).
The prevalence of osteoporosis shown in Brazilian 
studies is widely variable (from 22.2% to 33.8%) be-
cause of differences in sample sizes, eligibility criteria, 
and methodologies (3). The prevalence of all types of 
bone fragility fracture is high, ranging from 11% to 
23.8% associated with a high incidence of recurrent 
falls. Mortality rate ranges from 21.5% to 30%, with a 
high rate of physical impairment, and deterioration of 
the quality of life (3). 
In Brazil, annual osteoporosis treatment costs are 
775 dollars per patient (postmenopausal women), ac-
cording to Kowalski and cols (4). A probably underesti-
mated cost of hip fracture in a Brazilian public hospital 
showed something around US$ 3,940.00 for a mean of 
11 days of hospitalization (5), and mortality rate after 
6 months as high as 23.3% (6). In private hospitals, the 
mean hospitalization period for hip fractures was 9.21 
days with a cost of US$ 12,000.00, mainly related to 
medical and surgical procedures (5). 
The aim of osteoporosis treatment is to prevent 
fractures, and involves pharmacological and non-phar-
macological approaches, and treatments which will be 
reviewed below.
NON-PHARMACOLOGICAL TREATMENT
Peak bone mass is achieved during the third decade of 
life, and it is mainly determined by genetic influence 
and, to a lesser extent, by the modifiable aspects in life 
style and health status. Factors such as nutrition, hor-
monal status, physical exercise, medical conditions, drug 
abuse, alcohol or tobacco can interfere with the peak of 
bone mass. Patients should be encouraged to stop smok-
ing and reduce excessive alcohol and caffeine intake (7).
Fall prevention strategies should be discussed with 
the patients with focus on their homes. Some medical 
conditions need to be addressed such as dizziness, pos-
tural hypotension, poor vision, and inadequate foot-
wear (7). 
Several studies demonstrate that physical exercise 
programs including impact exercises, specific strength 
training, balance and coordination training may main-
tain or increase spine and hip bone mineral density, as 
well as decrease the frequency of falls among osteopo-
rotic and osteopenic patients (8).
CALCIUM 
Prolonged low calcium intake leads to a negative cal-
cium balance with compensatory secondary hyperpara-
thyroidism, which increases bone resorption and the risk 
of fractures. According to the US Institute of Medicine 
(IOM), the recommended daily calcium intake for post-
menopausal women is 1,200 mg, with an upper limit 
of 2,000 mg (9), preferentially obtained from the diet. 
This information can be assessed by a quick question-
naire and, if this goal is not met, the initial strategy is to 
incentivize consumption, especially of dairy products. If 
this is not possible, calcium supplements have to be con-
sidered. Pinheiro and cols. reported an average intake of 
414 mg a day in Brazilian postmenopausal women (10). 
Many calcium salts are available but, carbonate and 
citrate are the most commonly used. Calcium carbon-
ate has 40% elemental calcium, whereas citrate has 21%. 
The dissolution of calcium citrate is less dependent on 
the presence of gastric acidity than carbonate. This con-
dition is especially relevant for the elderly, the users of 
proton pump inhibitors and after bariatric surgery. It is 
not recommended that patients receive more than 500 
mg per dose, to improve absorption. In some patients, 
nausea, dyspepsia, and constipation can follow calcium 
supplementation, reducing treatment compliance (11).
Recently, controversy has arisen based on reports 
of increased cardiovascular risk associated with calcium 
supplementation. Publications with the opposing view 
have also been recently published, including a meta-
analysis and a randomized controlled trial with long 
term follow-up (12,13). This leads to the question of 
whether calcium supplementation is beneficial for the 
bone system, but deleterious for the cardiovascular sys-
tem. According to the ASBMR Professional Practice 
Committee in 2011, the weight of evidence is insuf-
ficient to conclude that calcium supplements cause ad-
verse cardiovascular events; however, the debate still 
continues (14).
VITAMIN D
The contribution of diet as a source of vitamin D is very 
limited and its concentrations are mainly dependent on 
the skin formation after UVB radiation. The enormous 
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social changes that occurred in the last century justify 
the high prevalence of vitamin D deficiency observed 
in virtually all regions of our planet. The aging of the 
population, the rise in obesity, the more reclusive habits 
in large cities, and the indiscriminate use of sunscreen 
have caused a currently generalized inadequate vitamin 
D status. Lower concentrations of vitamin D are asso-
ciated with elevated levels of PTH and, consequently, 
high resorption rate, and high risk of fractures. The rec-
ognition of these changes allowed a recent review on 
the Table of Vitamin D intake recommendations by the 
Institute of Medicine, in the U.S. 
The IOM recommends a vitamin D daily dietary al-
lowance of 600 IU for 51-70 years old women, and 
800 IU for those older than 70 years old, with an upper 
limit of 4,000 IU (9). However, the Endocrine Society 
guideline recommends 1,500-2,000 IU daily, with an 
upper limit of 10,000 IU (15).
Vitamin D status is best assessed by measuring levels 
of 25(OH)D. The IOM Committee considers 20 ng/
mL to be the level necessary for good bone health in 
practically all individuals (9). However, the American 
Endocrine Society strongly suggests that, for an ad-
equate vitamin D status, 25(OH)D should be higher 
than 30 ng/mL (15). Many authors consider 30 ng/
mL as the lower limit of the normal range, because this 
level is associated with lower PTH concentrations, with 
greatest calcium absorption, highest bone mineral den-
sity (BMD), reduced rates of bone loss, reduced rates 
of falls, and reduced fracture rates (16). In adults with 
very low 25(OH)D levels (under 20 ng/mL), a 7,000 
IU daily or 50,000 units weekly, for 6 to 8 weeks or 
longer, may be necessary (15). In our experience, doses 
higher than 1,000 IU/day of vitamin D3 are necessary 
to maintain 25-hydroxyvitamin D [25(OH)D] within 
normal range (> 30 ng/mL) in osteoporotic patients. 
Vitamin D deficiency and insufficiency is very com-
mon in Brazil, especially among the elderly individuals, 
even in sunny regions. The main determinants are age, 
sex, latitude, ethnicity, and sunlight exposure (17,18). 
HORMONE REPLACEMENT THERAPY (HRT)
There is evidence that bone loss starts 2-3 years prior 
to the last menses, and it is accelerated with menopause 
due to estrogen deprivation. This process continues for 
up to 5-10 years. Estrogen deficiency is associated with 
an increase in the lifespan of osteoclasts and a concomi-
tant decrease in osteoblast lifespan. It is also associated 
with increases in bone marrow levels of a number of 
pro-resorptive cytokines, including TNF-α, IL-1 α, 
and others (19). These cytokines expand the pool of 
osteoclast precursor cells, and increase expression of the 
key molecule regulating osteoclast development, activ-
ity, and lifespan: receptor activator of nuclear factor B 
ligand (RANKL), by osteoblasts and other cells in the 
bone microenvironment (19). 
There is considerable evidence that even the low 
residual levels of estrogen present in postmenopausal 
women are important in reducing bone resorption, and 
that women with breast cancer treated with aromatase 
inhibitors are at increased risk of bone loss (19).
This suppression of osteoclast activity by estrogen 
replacement therapy has been used effectively for de-
cades, and was the mainstay of prevention and treat-
ment of postmenopausal osteoporosis. Nowadays, the 
primary indication is the treatment of moderate and se-
vere menopausal symptoms (i.e., vasomotor symptoms, 
vaginal atrophy) (1). 
Wells and cols. published a meta-analysis that used 
57 randomized, placebo-controlled trials evaluating the 
effect of HRT in postmenopausal women. They dem-
onstrated that estrogen was significantly more effective 
than placebo in preserving and increasing BMD, and 
the discontinuation of estrogen resulted in bone loss 
at a rate similar to that seen in early menopause (20).
In the same study, Wells and cols. observed that 
HRT showed a trend towards reduced incidence of ver-
tebral fractures [relative risk (RR) 0.66, 95% confidence 
interval (CI) 0.41–1.07; 5 trials] and non-vertebral 
fractures (RR 0.87, 95% CI 0.71–1.08; 6 trials) (20).
HRT is associated with an increased risk of ad-
verse health outcomes in the long-term therapy, such 
as stroke and venous thromboembolic events. Women 
receiving estrogen and progestogen showed a small but 
significant increase in breast cancer in the Women’s 
Health Initiative study. However, the use of isolated 
estrogen therapy in hysterectomized women reduced 
23% the incidence of invasive breast cancer compared 
with placebo (p = 0.06, not significant) (21).
SELECTIVE ESTROGEN RECEPTOR MODULATORS 
(SERMS)
SERMs bind to the estrogen receptor (ER) with high 
affinity, and mediate transcriptional events as an agonist 
(bone and cardiovascular system) or antagonist (breast 
and in some cases endometrium), depending on the 
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target tissue. Raloxifene is approved for the prevention 
and treatment of postmenopausal osteoporosis (60 
mg/day). The effects of raloxifene on markers of bone 
turnover have generally been more modest (e.g., 30-
40% reduction) than with bisphosphonate therapy (50-
70%) (22). The same response was observed in BMD 
(23). The MORE (Multiple Outcomes of Raloxifene 
Evaluation) study demonstrated a 30% reduction of 
vertebral fracture risk (RR, 0.7; 95%CI, 0.5-0.8), but 
not in non-vertebral fractures during a follow-up of 
3 years (24). In the CORE study, an extension of the 
MORE study, it has been shown that raloxifene therapy 
had no effect on non-vertebral fracture risk after 8 years 
(25). Raloxifene also reduced the risk of ER-positive-
invasive breast cancer (RR, 0.24; 95% CI, 0.15-0.40) 
and endometrial cancer (RR, 0.62; 95% CI, 0.35-1.08) 
(25,26). The RUTH (Raloxifene Use for The Heart) 
study, involving postmenopausal women with high 
risk of cardiovascular disease for 5 years, showed an 
increased risk of fatal stroke (HR, 1.49; 95% CI, 1.00-
2.24) and venous thromboembolism (HR, 1.44; 95% 
CI, 1.06-1.95) (27). 
In general, it is well tolerated, with transient occur-
rence of hot flushes and leg cramps in less than 10% 
of patients. Consequently, it is not recommended to 
symptomatic postmenopausal women (24).
Other new SERMs have been developed in recent 
years, but some were discontinued because of unac-
ceptable efficacy, safety, and/or tolerability profiles. 
The PEARL (Postmenopausal Evaluation and Risk 
Reduction with Lasofoxifene) Study evaluated the dose 
of 0.5 mg/d in 8,556 women, and showed a reduction 
of the vertebral fracture risk by 42% (HR, 0.58; 95% 
CI, 0.47-0.70) at 3 years, and non-vertebral fractures 
by 24% (HR 0.76; 95% CI, 0.64-0.91) at 5 years; risk 
of ER positive breast cancer (HR 0.19; 95% CI, 0.07-
0.56), coronary heart disease (HR 0.68; 95% CI, 0.50-
0.93), and stroke (HR, 0.64; 95% CI, 0.41-0.99), but 
increased the risk of venous thromboembolic events, 
vasomotor symptoms, and leg cramps. There was also 
an increased risk of uterine polyps and endometrial hy-
pertrophy, but no increased risk of endometrial cancer 
or hyperplasia (28).
A 5-year study of bazedoxifene (20 or 40 mg) 
showed a reduction of 35 and 40% of the risk of ver-
tebral fractures, respectively. There was an increase in 
BMD, reduced bone turnover marker levels, and favor-
able effects on lipid parameters. In a post-hoc analysis of 
a subgroup at high risk of fracture, the 20-mg dose sig-
nificantly reduced the risk of non-vertebral fracture by 
37% compared with the placebo. There was no stimula-
tory effect on the endometrium, but it was associated 
with increased vasomotor symptoms, leg cramps, and 
venous thromboembolism (29).
Both bazedoxifene and lasofoxifene have been ap-
proved for use in treatment of postmenopausal osteo-
porosis in the European Union, but they are not avail-
able in Brazil.
BISPHOSPHONATES
Bisphosphonates are the most used anti-resorptive 
agents in the world for the treatment of osteoporosis 
and are in use for three decades. They are synthetic 
analogues of pyrophosphate, with high affinity for hy-
droxyapatite. They strongly bind to the mineralized tis-
sue, especially in the active remodeling sites. They are 
removed from bone by osteoclasts during resorption 
and are not metabolized for excretion. Therefore, they 
can be rebound by the mineralized tissue again. Because 
of their characteristics, they can remain as long as 10 
years in the skeleton. Variations in the structure of the 
amino side chains of these drugs affect their pharma-
cological activity in terms of bone affinity and potency. 
The most potent molecules have a nitrogen-containing 
chain, such as alendronate, risedronate, ibandronate, 
and zoledronate. Skeleton-binding affinity increases in 
this rank order: risedronate, ibandronate, alendronate, 
and zoledronate (30). 
The mechanism of action is the inhibition of farne-
syl diphosphate synthase, an enzyme of the mevalonate 
pathway, and prevention of the prenylation of GTP-
binding proteins, essential in the cytoskeletal osteoclast 
function and metabolism. Basically, bisphosphonates 
decrease bone turnover leading osteoclasts to apopto-
sis. The rank order of potency for inhibiting farnesyl 
diphosphate synthase is zoledronate<risedronate<iband
ronate<alendronate (30,31). The increase of bone mass 
observed in many trials is related to the secondary min-
eralization of the preformed osteons, and not because 
of increased bone formation (32). 
Alendronate can be given orally once a week (70 
mg), ibandronate once a month (150 mg), and rise-
dronate once a week or once a month (35 mg and 150 
mg, respectively). Oral bisphosphonates are poorly ab-
sorbed (less than 1%), and the dose has to be adminis-
tered with plain water only, after an overnight fast, and 
followed by 30-60 minutes without eating or drink-
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ing. The patients need to stand upright for one hour 
to prevent gastroesophageal reflux and damage to the 
mucosa (30,31). 
Ibandronate can also be given intravenously (IV) 
every 3 months (3 mg), and zoledronate once a year 
(5 mg IV). The main side effect of this administration 
is an auto-limited flu-like syndrome (acute phase reac-
tion) due to release of cytokines (TNF-α, IFN-γ, and 
IL-6), causing mild fever and muscle pain that can be 
controlled with anti-pyretic drugs. This reaction usu-
ally subsides in 1 or 2 days, and gets milder with the 
subsequent infusions (30,31).
Fifty per cent of the absorbed dose binds to the 
bones, and the rest is excreted in the urine. Renal tox-
icity may occur with rapid IV administration. Use is not 
recommended for patients with creatinine clearance 
lower than 30–35 mL/min. These compounds should 
be used with caution in pre-menopausal women of 
childbearing potential, because their effects in human 
fetus are still unknown (30,31).
Alendronate was the first bisphosphonate approved 
by the FDA for the prevention and treatment of osteo-
porosis. The once-weekly administration (70 mg) im-
proved the use and tolerability with the same or better 
efficacy than the daily therapy (10 mg) (33). In the FIT 
(Fracture Intervention Trial) study, there was a 47% re-
duction in new morphometric vertebral fractures (RR, 
0.53; 95% CI 0.41-0.68), and 51% in hip fractures (RR, 
0.49; 95% CI, 0.23-0.99) in individuals with one prior 
vertebral fracture at least (34). In those without frac-
tures, alendronate reduced the risk of radiographic ver-
tebral fractures in 44% (RR, 0.56; 95% CI, 0.39-0.80) 
in 4 years (35). In the FOSIT (Fosamax International 
Trial) study, alendronate reduced the risk of non-verte-
bral fractures in 47% (36). In the FLEX (Fracture Inter-
vention Trial Long-term Extension) study, switching to 
placebo for 5 years resulted in declines in BMD in total 
hip and spine, but mean levels remained at or above 
pretreatment levels 10 years earlier. After 5 years, the 
cumulative risk of non-vertebral fractures (RR, 1.00; 
95% CI, 0.76-1.32) was not significant. Among those 
who continued, there was a significantly lower risk of 
clinically recognized vertebral fractures (RR, 0.45; 95% 
CI, 0.24-0.85), but no significant reduction in mor-
phometric vertebral fractures (37). 
Risedronate was evaluated in the US and multi-
national VERT (Vertebral Efficacy With Risedronate 
Therapy) studies, showing a reduction of new vertebral 
(41% and 49%, respectively) and non-vertebral fractures 
(39% and 33%, respectively) during 3 years, at least in 
women with prior vertebral fracture (38). In the Hip In-
tervention Program Study Group, risedronate showed a 
reduction of 40% in women with osteoporosis (RR, 0.6; 
95% CI, 0.4-0.9) (39). Risedronate is given in a once a 
week (35 mg) or monthly (150 mg) dose.
An oral daily dose (2.5 mg) and an intermittent dose 
(20 mg every other day for 12 doses every 3 months) 
of ibandronate were evaluated in the BONE (oral iBan-
dronate Osteoporosis vertebral fracture Trial in North 
America and Europe) study. After 3 years, daily and inter-
mittent oral ibandronate significantly reduced the risk of 
new morphometric vertebral fractures by 62% and 50%, 
respectively, versus placebo. The overall population was 
at low risk of osteoporotic fractures. Consequently, the 
incidence of non-vertebral fractures was similar between 
the ibandronate and placebo groups. However, findings 
from a post-hoc analysis showed that the daily regimen 
reduced the risk of non-vertebral fractures (69%) in a 
higher-risk subgroup (femoral neck BMD T-score < 
-3.0) (40). The MOBILE (Monthly Oral IBandronate 
In LadiEs) study, evaluated the monthly dose (50/50, 
100, and 150 mg) compared with the daily regimen 
during 2 years. All monthly regimens were proven to be 
non-inferior, and the 150 mg regimen superior, to the 
daily regimen. All monthly regimens produced similar 
hip BMD gains, which were greater than those of the 
daily regimen (41). The DIVA (Dosing IntraVenous 
Administration) study compared two regimens of in-
termittent intravenous injections of ibandronate (2 mg 
every 2 months, and 3 mg every 3 months) with a regi-
men of 2.5 mg of oral ibandronate daily, which are at 
least as effective as the daily regimen of 2.5 mg by oral 
route. The primary endpoint was different from baseline 
in lumbar spine BMD at 1 year (42).
The HORIZON (Health Outcomes and Reduced 
Incidence with Zoledronic Acid Once Yearly) study 
evaluated the efficacy of 5 mg zoledronate during 3 
years. There was a reduction of the risk of morphomet-
ric vertebral fracture by 70% (RR, 0.30; 95% CI, 0.24-
0.38), and hip fracture by 41% (HR, 0.59; 95% CI, 
0.42-0.83). Non-vertebral fractures, clinical fractures, 
and clinical vertebral fractures were reduced by 25%, 
33%, and 77%, respectively (43). A reduction of 35% 
in new clinical fractures in patients with prior fractures 
was documented in another study, along with a reduc-
tion in mortality (28%) (44). Recently, the extension 
FPT (HORIZON-Pivotal Fracture Trial) study showed 
the benefits of a 6-year treatment of zoledronate. 
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In years 3 to 6, femoral neck BMD remained constant 
in the zoledronate group, and dropped slightly in the 
discontinuing group (between-treatment difference = 
1.04%; 95% CI, 0.4-1.7) but remained above pretreat-
ment levels. Other BMD sites showed similar differen-
ces. New morphometric vertebral fractures were lower 
in the zoledronate group (odds ratio = 0.51), whereas 
other fractures were not different (45).
The most common adverse events reported with 
the use of oral bisphosphonates are related with gastro-
esophageal intolerance, reported in up to 10% of trial 
participants (46,47). An increased risk of atrial fibril-
lation was reported in the HORIZON trial (43), but 
other observational studies have failed in detecting an 
increased risk with any of the bisphosphonates (47).
Osteonecrosis of the jaw (ONJ) has been reported 
primarily in patients with cancer who have received large 
and cumulative doses of intravenous bisphosphonates. 
This condition is defined as exposure of necrotic bone in 
the oral cavity, not healing for 6-8 weeks, in the absence 
of radiotherapy and jaw metastases. In patients with os-
teoporosis treated with bisphosphonates, ONJ is rare, ac-
counting for 0.8-5.0% of the reported cases, and no cas-
es have been identified in clinical trials with alendronate, 
ibandronate, or risedronate. In the HORIZON-FPT, 
two cases of ONJ were reported among 7,765 patients, 
one in the placebo, and one in the zoledronate group 
(43). The incidence of ONJ is estimated at 0.9/100,000 
patient-years of treatment among patients who receive 
oral bisphosphonate therapy, and the causal association 
is unproven (30,46,47). According to the American 
Dental Association General Treatment Recommenda-
tions 2011, practitioners generally should not modify 
routine dental treatment solely because of the use of 
anti-resorptive agents. An oral health program consist-
ing of sound hygiene practices and regular dental care 
may be the optimal approach for lowering ONJ risk. No 
validated diagnostic technique exists to determine which 
patients are at increased risk of developing ONJ. Dis-
continuing bisphosphonate therapy may not lower the 
risk, but may have a negative effect on low-bone-mass-
treatment outcomes (48).
Cases of atypical low-trauma subthrocanteric and 
femoral shaft fractures have been reported in patients 
receiving long-term bisphosphonates. Prior to the frac-
ture, patients reported prodromal symptoms of pain 
(typically groin or thigh). Radiographic findings are the 
thickening of the cortex in the lateral aspect of the prox-
imal femur, which is the site of high tensional stresses. 
A complete atypical fracture is displayed in addition to 
a straight transverse fracture line and median cortical 
spiking (7). Attention has been drawn to an association 
between this kind of fractures and the use of bisphos-
phonates, possibly related to long-term suppression of 
bone turnover (30,47). However this hypothesis comes 
from retrospective case series with small numbers of pa-
tients involved. There is no randomized controlled trial 
evidence of an increase in the risk of atypical fractures. 
There is also a possible association of reduced bone 
turnover induced by bisphosphonates and the other risk 
factors, such as younger age at beginning or concomi-
tant therapy with corticosteroids, proton pump inhibi-
tors, or other anti-resorptive agents (30,47).
The ideal duration of treatment with bisphospho-
nates is uncertain at this time. There is considerable 
evidence showing that anti-resorptive agents are ef-
fective in reducing fracture risk, and that they are well 
tolerated for over 3 to 5 years. It is a reasonable ques-
tion when considering bisphosphonate therapy, how-
ever, because these drugs accumulate in the skeleton, 
leading to a reservoir that continues to be released for 
months or years after treatment is discontinued. Stop-
ping alendronate after 10 years of treatment at a dose 
of 10 mg daily (which should be the same of 70 mg 
weekly), the amount of alendronate released from bone 
over the next several months or years would be equiva-
lent to taking one fourth of the usual dose (2.5 mg 
daily or 70 mg once a month). There is a concern that 
long-term treatment has the potential to oversuppress 
bone remodeling and inhibit repair of microdamage, 
cause excessive mineralization, and cause an increase in 
microcracks. The data from the FLEX trial (37) sug-
gest that a subset of patients may safely take a break 
from alendronate after 5 years of therapy without ex-
periencing a rapid decline in BMD. The data suggest 
that, although there is some residual benefit in terms 
of fracture reduction for some time after a 3- to 5-year 
course of bisphosphonate therapy, continuing treat-
ment for 10 years is better for some patients (high risk 
of fracture). Decisions regarding discontinuation must 
be individualized and based upon the assessment of on-
going fracture risk (30).
CALCITONIN
The PROOF (Prevent Recurrence Of Osteoporotic 
Fractures) study showed that a dose of 200 IU of salm-
on calcitonin nasal spray significantly reduced the risk 
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of new vertebral fractures by 33% (RR, 0.67, 95% CI, 
0.47-0.97) and 36% in women with prevalent fractures 
(RR = 0.64, 95% CI, 0.43-0.96). Occasional rhinitis 
can occur. Headache, flushing, nausea and diarrhea 
have been reported more commonly with subcutane-
ous dose than with intranasal calcitonin. There is no 
data on hip or non-vertebral fracture risk reduction 
(49). Nowadays, calcitonin is relegated to second or 
third place as the agent of choice for the treatment of 
osteoporosis.
DENOSUMAB
Denosumab is a human monoclonal antibody that 
inhibits RANKL and, consequently, osteoclastogenesis. 
It is administered as a 60-mg subcutaneous injection 
every 6 months. Its clearance occurs by means of the 
reticuloendothelial system and not by renal excretion. 
Therefore, denosumab can be given to patients with 
renal impairment. The FREEDOM (Fracture Reduc-
tion Evaluation of Denosumab in Osteoporosis Every 
6 Months) trial evaluated the efficacy of denosumab 
during 3 years; the treated group had significant gains 
in lumbar spine (9.4%) and total hip BMD (4.8%). De-
nosumab reduced the risk of new radiographic verte-
bral fracture in 68% (RR, 0.32; 95% CI, 0.26-0.41), 
hip fracture in 40% (HR, 0.60; 95% CI, 0.37-0.97) 
and non-vertebral fracture in 20% (HR 0.80; 95% CI, 
0.67-0.95). Cellulitis was more frequent in patients 
taking denosumab compared with the placebo (0.3% 
vs. < 0.1%), although the absolute risk was very low 
(50). In the long-term group, BMD further increased 
in cumulative 6-year gains of 15.2% (lumbar spine) and 
7.5% (total hip). In the long-term group, fracture inci-
dence remained low and rare cases of ONJ have been 
reported (51). Patients discontinuing denosumab ex-
perienced a fast decrease in BMD during the first 12 
months, with the subsequent rate of BMD losses being 
similar to the placebo, demonstrating that denosumab 
does not confer a residual effect following cessation of 
therapy (52). Long-term treatment with denosumab 
was associated with a sustained increase on BMD, as 
well as low bone markers, and maintained the vertebral 
and non-vertebral anti-fracture efficacy over 6 years. Six 
participants had events of ONJ confirmed by adjudi-
cation. One participant had a fracture adjudicated as 
consistent with atypical femoral fracture (51).
TERIPARATIDE
Intermittent administration of low-dose PTH enhances 
osteoblast activity and bone formation. Two PTH pep-
tides have been approved for the treatment of osteo-
porosis: teriparatide (PTH 1-34) and PTH 1-84, but 
only teriparatide is available in Brazil. It is administered 
as a 20-mcg subcutaneous daily injection. There was 
a 65% and 54% reduction in fracture risk in vertebral 
and non-vertebral fractures. Due to a small number of 
hip fractures, no significant fracture risk reduction was 
demonstrated (53). The concomitant use of bisphos-
phonates may attenuate bone mass improvement seen 
with PTH alone, but the administration of an anti-re-
sorptive agent has to be considered after the treatment 
in order to maintain the bone gain achieved (54). Max-
imum treatment duration of 2 years is recommended 
because preclinical studies showed the development 
of osteosarcoma in rats (53). Asymptomatic hypercal-
cemia, occasional nausea, dizziness, leg cramps, and 
headache were associated with teriparatide use. Teripa-
ratide is contraindicated in clinical situations with high 
risk of osteosarcoma, such as children and adolescents, 
Paget’s disease, bone metastasis, skeletal irradiation, or 
unexplained elevations of alkaline phosphatase. The use 
of teriparatide is limited to severe osteoporosis because 
of the high cost of the treatment.
STRONTIUM RANELATE
Strontium ranelate contains two atoms of strontium, 
which is a divalent cation, like calcium. It has a dual 
action, increasing bone formation and decreasing 
resorption, but its exact mechanism of action is still 
unclear. The SOTI (Spinal Osteoporotic Therapeu-
tic Intervention) trial showed a risk reduction of 49% 
in the first year of treatment with 2 g daily, and of 
41% during the three-year study (RR, 0.59; 95% CI, 
0.48-0.73) (55). The TROPOS (TReatment Of Pe-
ripherial OSteoporosis) trial showed a reduction of 
19% on non-vertebral fracture, and among women at 
high risk of hip fracture, the reduction for hip fracture 
was 36% (56). The most common side effects were 
nausea, diarrhea, and mild and transient elevation 
in creatine kinase. It is contraindicated in patients at 
high risk of thromboembolic events. A few cases of 
hypersensitivity were described, with eosinophilia and 
systemic symptoms. Long-term treatment with stron-
tium ranelate was safe and associated with a sustained 
increase on BMD and in the anti-fracture efficacy over 
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10 years (57). As strontium has a higher atomic num-
ber than calcium, it attenuates more X-rays than cal-
cium does. This attenuation can result in an overesti-
mation of BMD that requires an adjustment for bone 
strontium content (58). 
NEW OSTEOPOROSIS TARGETS AND NEW 
MECHANISMS OF ACTION
Cathepsin K inhibitors – Odanacatib
Cathepsin K is a lisossomal enzyme produced by the os-
teoclast to break down the bone matrix during resorp-
tion process, and odanacatib (ODN) is a specific in-
hibitor of this enzyme. The phase II study showed that 
women receiving odanacatib for 5 years gained BMD 
in spine and hip, with larger reductions in bone resorp-
tion than in bone formation markers. Discontinuation 
of ODN resulted in reversal on these effects, with fast 
bone loss. Treatment with ODN for up to 5 years was 
generally well-tolerated (59).
Antiesclerostin antibodies
Sclerostin is a protein produced almost exclusively by 
osteocytes and its function is to prevent the Wnt sig-
naling in osteoblasts. The activation of Wnt pathway 
in the cell membrane of osteoblasts strongly induces 
bone formation. New monoclonal antibodies against 
sclerostin have been developed and are new promising 
therapeutic goal for osteoporosis.
CONCLUSION
In summary, osteoporosis is a very common clinical 
situation, with an expected trend to and increasing 
incidence in the next decades due to the worldwide 
aging of the population. Bone loss and fractures follow 
the decrease in estrogen levels in the postmenopausal 
period, which increases osteoclast activity and, subse-
quently, bone resorption. The adequacy of calcium in-
take and vitamin D status are priority measures before 
starting osteoporosis treatment with specific drugs, as 
well as encouraging physical activity and prevention of 
falls. Several drugs are already available with proven 
efficacy against fractures and excellent safety profiles. 
The challenge today is to improve the detection of os-
teoporosis and convince healthcare professionals to re-
fer at-risk patients for treatment.
Disclosure: S. S. Maeda is a speaker for Eli Lilly do Brasil and 
Sanofi, and M. Lazaretti-Castro has received research grants from 
Amgen, Eli Lilly do Brasil, and MSD, and speaker and consultant 
fees from Eli Lilly do Brasil, Sanofi, and Mantecorp-Farmasa. 
Note: After this article was accepted, a new statement of Euro-
pean Medicines Agency (EMA) was published with restrictions 
on the use of strontium ranelate caused by some data showing 
an increased risk of cardiovascular disease in patients receiving 
this treatment. The recommendations are that strontium ranelate 
should only be used to treat severe osteoporosis in postmeno-
pausal women and men at high risk of fracture, for whom treat-
ment with other medicinal products approved for the treatment 
of osteoporosis is not possible due to, for example, contraindica-
tions or intolerance. Strontium ranelate must not be used in pa-
tients with established, current or past history of ischaemic heart 
disease, peripheral arterial disease and/or cerebrovascular disease, 
those with uncontrolled hypertension, venous thromboembolic 
event, or temporary or permanent immobilization*.
* European Medicines Agency (EMA). Available: http://www.
ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
referrals/Protelos_and_Osseor/human_referral_prac_000025.
jsp&mid=WC0b01ac05805c516f.
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